Portal de Periódicos da CAPES

Concurrent Weekly Nedaplatin, External Beam Radiotherapy and High-Dose-Rate Brachytherapy in Patients with FIGO Stage IIIb Cervical Cancer: A Comparison with a Cohort Treated by Radiotherapy Alone

2010; Karger Publishers; Volume: 69; Issue: 4 Linguagem: Inglês

10.1159/000273207

1423-002X

Seiji Mabuchi, Hiromi Ugaki, Fumiaki Isohashi, Yasuo Yoshioka, Kumiko Temma, Namiko Yada-Hashimoto, Takashi Takeda, Toshiya Yamamoto, Kiyoshi Yoshino, Ryuichi Nakajima, Chie Kuragaki, Ken‐ichirou Morishige, Takayuki Enomoto, Takehiro Inoue, Tadashi Kimura,

Uterine Myomas and Treatments

<i>Objectives:</i> The aim of this study was to evaluate whether nedaplatin-based concurrent chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) is superior to radiotherapy (RT) alone in patients with FIGO stage IIIb cervical cancer. <i>Methods:</i> The records of 41 consecutive women treated either with nedaplatin-based CCRT using HDR-ICBT (n = 20) or RT alone (nonrandomized control group, n = 21) for stage IIIb cervical cancer were retrospectively reviewed. The activity and toxicity were compared between the two treatment groups. Progression-free survival (PFS) and overall survival (OS) were the main endpoints. <i>Results:</i> The 5-year overall survival rates in the CCRT and RT groups were 65 and 33.3%, respectively. The median OS of the CCRT and RT groups were 60 and 29 months, respectively. CCRT was significantly superior to RT alone with regard to PFS (p = 0.0015) and OS (p = 0.0364). The frequency of acute grade 3–4 toxicity was significantly higher in the CCRT group than in the RT group. However, no statistically significant difference was observed with regard to severe late toxicity. <i>Conclusions:</i> Nedaplatin-based concurrent chemoradiotherapy was safely performed and significantly improved the prognosis of patients with FIGO stage IIIb cervical cancer. This treatment can be considered as an alternative to cisplatin-based chemoradiotherapy in this patient population.